Floatz logo

FLUOROURACILUM

Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban)

Samsung Medical CenterSmall moleculePhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban) cohort.

Asset / SponsorPhaseRating
Edoxaban
Samsung Medical Center
Phase 2/3B
CIS-DIAMMINEDICHLOROPLATINUM II
Samsung Medical Center
Phase 2/3B
Enoxaparin
Samsung Medical Center
Phase 2/3B
Calcium folinate pentahydrate
Samsung Medical Center
Phase 2/3B

Same molecule, other indications

FLUOROURACILUM is also rated in:

colon carcinomaDormant
A
Indicative ·
82 / 100
View asset →
Unresectable or Metastatic Colorectal CancerDormant
BBB
Indicative ·
79 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →